Ask people with Ehlers-Danlos syndrome how long it took to get a name for what was happening to them, and the answer is often measured in years, sometimes decades. This group of hereditary connective tissue disorders affects the body’s ability to produce or process collagen, the protein that acts as the glue for skin, joints, and internal organs. Collagen is found throughout the body, so the symptoms are widespread too: chronic pain, joint instability, fatigue, dizziness, gut problems, and repeated injuries. Each is usually looked at on its own instead of as part of one connective tissue disorder. That is a big reason why an Ehlers-Danlos syndrome diagnosis can be delayed or misdirected, especially in hypermobile EDS, where there is still no lab test and diagnosis relies on clinical evaluation.
One of the primary reasons this syndrome remains under the radar is the historical perception that it is an extremely rare occurrence. For decades, medical students were taught that these types of connective tissue issues were unlikely to be encountered in a standard clinical setting. This has led to a significant knowledge gap where many healthcare providers are not trained to look for the subtle signs of systemic joint hypermobility or skin hyperextensibility. When a patient arrives with persistent discomfort, they are often treated for the immediate symptom rather than the systemic cause. This lack of awareness means that many individuals live for years, or even decades, without understanding the root cause of their physical challenges.
The complexity of the clinical presentation further complicates the path to a formal Ehlers-Danlos syndrome diagnosis. There are thirteen different subtypes of the condition, each with its own specific criteria and genetic markers, so the diagnostic process requires a high level of specialist knowledge. For many, the most common form is the hypermobile subtype, which currently lacks a known genetic test. This means doctors must rely entirely on clinical observation and a specific set of physical criteria. If a clinician is not familiar with the Beighton score or the systemic manifestations of fragile tissues, they may simply dismiss a patient as being double jointed or having a high level of flexibility without realizing the internal complications that accompany it.
Challenges in Identifying Chronic Pain and Fatigue
Chronic pain and fatigue are two of the most debilitating aspects of this condition, yet they are also the symptoms most likely to be misinterpreted by medical professionals. In many cases, patients are told that their pain is a result of lifestyle factors, stress, or even psychological issues. The pain associated with connective tissue laxity is often widespread and migratory, so it does not always fit the neat patterns of localized injury. This leads to a frustrating cycle where patients seek help for joint instability only to be told their X-rays and scans look normal. The microscopic nature of collagen defects means that standard imaging often fails to capture the true extent of the structural instability within the joints.
Fatigue is another significant hurdle that frequently leads to misdiagnosis. Many patients are initially told they have chronic fatigue syndrome or fibromyalgia because these conditions share similar overlaps in symptom profiles. While these diagnoses may provide some level of validation, they often miss the mechanical cause of the exhaustion. For someone with fragile connective tissue, the body must work significantly harder simply to keep joints in place and maintain an upright posture. This constant physical exertion leads to a profound level of depletion that is not easily rectified by rest. Without addressing the underlying stability issues, the fatigue remains a persistent and misunderstood barrier to daily functioning.
The psychological impact of being unheard cannot be overstated in this context. When a patient is repeatedly told that there is nothing physically wrong with them despite their lived experience of pain, it creates a sense of medical trauma. This often results in patients withdrawing from the healthcare system or becoming hesitant to report new symptoms. It is vital for clinicians to consider how these symptoms connect. By recognizing that joint instability, digestive issues, and autonomic dysfunction can all stem from a single connective tissue defect, the medical community can begin to reduce the time it takes for a patient to receive the correct support.
Increasing the Role of Specialist Input and Research
The role of specialist input is critical in bridging the gap between clinical suspicion and a confirmed diagnosis. Rheumatologists, geneticists, and physiotherapists who specialize in hypermobility are often the only professionals equipped to navigate the nuances of the condition. These specialists look beyond the surface level symptoms to check the integrity of the vascular system, the skin, and the internal organs. They understand that a patient might present with something as seemingly unrelated as dental crowding or easy bruising, which are actually key indicators of a broader systemic issue. Access to these specialists is often limited by geography or insurance, which further contributes to the underdiagnosis of the condition in the general population.
The field knows the current framework needs to evolve, and new guidelines are on the way. The 2017 international classification has been the backbone for diagnosis, but a major global update is now underway through the “Road to 2026” process. The aim is to publish revised diagnostic criteria and pathways in late 2026, with the Ehlers-Danlos Society stating that the new framework is scheduled for publication on December 1, 2026. That matters because better criteria should mean earlier recognition, clearer differentiation between hEDS and HSD, and more consistent routes into specialist care.
Participation in EDS clinical trials is becoming a more prominent pathway for people to reach newer approaches to care and to contribute to the collective knowledge of the disorder. These studies are essential for developing targeted therapies that move beyond simple symptom management. Research is currently exploring everything from the neurological impacts of the condition to the specific ways in which hormonal changes affect joint laxity in different stages of life.
Innovation in data collection and patient registries is also playing a significant role in improving outcomes. By gathering information from a global cohort of patients, researchers can identify patterns that were previously invisible in smaller study groups. This data driven approach allows for a more nuanced understanding of the various comorbidities that often accompany the syndrome, such as mast cell activation or postural orthostatic tachycardia syndrome. As our understanding of these associations grows, it becomes easier for doctors to spot the warning signs earlier in a patient’s life. This proactive approach is the key to preventing the long term joint damage and secondary complications that occur when the condition is managed incorrectly for years.
The Importance of Recognition in EDS Clinical Trials
Care is still gap filled, but research and EDS clinical trials are finally starting to move from description to action. There is still no single disease modifying treatment for hypermobile EDS, so management today often depends on tailored multidisciplinary care, including pain support, physical therapy, fatigue management, and joint protection. The direction of travel is improving, though: current research is refining diagnosis, exploring biology more deeply, and testing practical interventions that may improve pain, function, and participation, including active clinical studies in symptomatic hypermobility populations. In other words, the field is starting to move from “you’ve been missed” to “here’s a clearer path forward.”
Improving the visibility of these conditions is not just about better individual care; it is about changing the systemic approach to rare and complex diseases. When the medical community prioritizes the recognition of connective tissue disorders, it opens the door for more robust funding and public health initiatives. This recognition is particularly important for the development of new protocols in emergency medicine and surgery, where tissue fragility can lead to significant complications if the surgical team is unaware of the patient’s status. Increased awareness ensures that every part of the healthcare system is prepared to provide safe and effective care for those with fragile tissues.
As we look toward the future, the focus must remain on fostering partnerships between patients, clinicians, and researchers. Patients are the true experts in their own bodies, and their insights are invaluable for shaping the direction of future studies. When research is co-designed with the patient community, the outcomes are more relevant and impactful. This collaborative spirit is what will ultimately close the gaps in care and ensure that no one has to spend decades searching for an answer. By validating the experiences of those living with these challenges, we can build a healthcare environment that values precision, empathy, and thorough investigation over quick or superficial judgments.
The path forward requires a commitment to education at every level of the medical profession. From the initial training of medical students to the continuing professional development of experienced doctors, the nuances of Ehlers-Danlos syndrome must be integrated into the standard curriculum. This ensures that the next generation of healthcare providers is equipped to identify the signs of joint instability and systemic collagen issues early on. Education helps remove the stigma associated with chronic pain and gives doctors the confidence to make the specialist referrals that are so often the turning point in a patient’s life. If you want to learn more at your own pace, see what taking part in a study could involve, and use the medifit™ + readifit™ self-reflection tools to reflect on whether a trial could fit your health and your life.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, an AI native clinical trial navigation and decision-support platform, in the belief that technology earns its place in research only when it makes a study easier to understand and a decision easier to make. Understanding comes first. Decisions follow.